Last checked: August 7, 2026
A prospective multicenter diagnostic accuracy study published in Clinical Infectious Diseases (DOI: 10.1093/cid/ciag342) evaluated the LyocartE MTB near-point-of-care assay on paired sputum and tongue swab specimens from 689 participants with presumptive tuberculosis at three sites in China. The study reports high specificity for tongue swabs but lower sensitivity than sputum, with a notable drop-off in paucibacillary cases. This appraisal separates the study findings from their public health deployment implications and identifies the boundaries procurement teams must respect when interpreting the data.
1. Clinical Context: Why Tongue Swabs Are Being Evaluated for TB Near-POCT
Sputum collection remains the standard specimen for pulmonary tuberculosis diagnosis, but it presents practical barriers: some patients cannot produce sputum voluntarily, specimen quality varies, and biosafety handling of aerosol-generating specimens adds workflow complexity. Tongue swabs offer a non-invasive alternative that is easier to collect and does not require respiratory effort or sputum induction. These practical advantages motivate research into whether tongue-swab-based molecular assays could serve as an additional or complementary specimen type in TB diagnostic workflows.
However, a diagnostic accuracy study alone cannot establish that tongue swabs are ready to replace sputum in programmatic settings. Deployment requires WHO policy guidance, local regulatory authorization, and operational validation in the target population. The study appraised here provides accuracy data from a specific clinical context; it does not by itself authorize clinical deployment.
2. Study Design Appraisal: Multicenter Prospective Trial in China (N=689)
The study enrolled 689 participants with presumptive TB across three clinical sites in China. Paired sputum and tongue swab specimens were collected from each participant and tested with the LyocartE MTB assay, a near-point-of-care molecular test. The investigators used two reference standards to evaluate diagnostic accuracy:
- Composite microbiological reference standard — a combined reference combining culture and Xpert Ultra results, used to establish the presence or absence of TB disease.
- Sputum Xpert Ultra — used as a separate comparator to assess tongue-swab performance against an established molecular test on sputum.
The use of two distinct reference standards is methodologically important because each addresses a different question. The composite reference answers: how accurately does the tongue swab detect TB disease as defined by the combined gold standard? The sputum Xpert Ultra comparator answers: how closely does the tongue swab result agree with an established molecular test performed on sputum? Reporting both prevents conflating agreement with one assay against true disease status.
The study was independently verified via PubMed E-utilities (PMID: 42212698), confirming the multicenter design, enrollment size, and publication in a peer-reviewed journal.
3. Diagnostic Accuracy Data: Sputum vs. Tongue Swab Performance
The study reports different sensitivity values for tongue swabs depending on which reference standard was used. These must be stated separately and cannot be combined into a single number:
| Specimen Type | Reference Standard | Sensitivity | Specificity |
|---|---|---|---|
| Sputum | Composite microbiological reference standard (culture and Xpert Ultra) | 95.2% (95% CI: 91.3%–97.7%) | 98.6% (95% CI: 97.0%–99.5%) |
| Tongue swab | Sputum Xpert Ultra | 87.4% | 99.7% |
| Tongue swab | Composite microbiological reference standard | 84.1% | 99.7% |
Three observations are critical for interpreting these results:
- Tongue swab sensitivity differs by reference standard. The 87.4% figure reflects agreement with sputum Xpert Ultra, while the 84.1% figure reflects detection against the composite microbiological reference. Citing only the higher number without naming its comparator would misrepresent the evidence.
- Specificity was consistently high. At 99.7% in both comparisons, the tongue swab assay showed very few false positives. This high specificity is a strength of the tongue-swab approach.
- Sputum outperformed tongue swabs on sensitivity. Sputum achieved 95.2% sensitivity versus the composite reference, compared with 84.1% for tongue swabs against the same standard. The 11.1 percentage-point gap means tongue swabs missed more true TB cases than sputum in this study population.
These figures retain the study’s population (689 presumptive TB participants at three sites in China), specimen type (paired sputum and tongue swab), and comparator context. They should not be generalized to other populations, specimen collection protocols, or assay versions without further evidence.
4. Subgroup Analysis: Sensitivity Drop-Off in Smear-Negative Cases
The study performed subgroup analysis by smear status. Tongue swab sensitivity was lower in smear-negative (low-bacillary burden) cases compared with smear-positive cases. This finding has direct operational implications:
- Smear-negative patients represent a clinically important subgroup, as they are harder to diagnose and may include early or paucibacillary disease.
- The sensitivity gap means tongue swabs may miss cases that sputum-based testing would detect, particularly in patients with low bacterial loads.
- Programmatic use of tongue swabs as a standalone replacement for sputum in smear-negative populations would carry a higher risk of false negatives.
This subgroup finding reinforces the importance of not presenting tongue swabs as a universal replacement for sputum across all TB diagnostic workflows. The diagnostic accuracy data supports tongue swabs as a complementary specimen type with specific performance characteristics, not as a drop-in substitute.
5. Public Health Deployment Boundaries: Diagnostic Accuracy Is Not WHO Endorsement
A single diagnostic accuracy study, regardless of its quality, does not establish readiness for programmatic deployment. The following boundaries apply to the interpretation of this evidence:
WHO Policy
The study provides diagnostic accuracy data. It does not represent a WHO policy recommendation for tongue swab-based TB testing. WHO develops separate policy guidance through systematic evidence review, GRADE evaluation, and expert consultation. As of the checking date, no WHO policy endorsement for universal replacement of sputum with tongue swabs in initial TB diagnosis has been issued based on this study alone.
Regulatory Authorization
Clinical deployment of the LyocartE MTB assay on tongue swabs requires local regulatory authorization in the jurisdiction of use. Diagnostic accuracy data from a clinical study does not substitute for regulatory clearance, registration, or approval. Procurement teams must verify the regulatory status of the assay in their jurisdiction independently.
Population Limitations
The study enrolled 689 participants with presumptive TB at three sites in China. The results apply to this study population and setting. Extrapolating the findings to unstudied populations — including pediatric patients, HIV-coinfected individuals, asymptomatic screening populations, or settings with different TB prevalence — is not supported by the evidence as presented.
Procurement Decision Framework
For procurement teams considering tongue-swab-based molecular assays, the following framework separates what the evidence supports from what it does not:
For comparison with device-level procurement and implementation questions, see the site’s fully automated molecular POCT procurement guide and its CRP/SAA POCT evidence appraisal. Neither companion article validates LyocartE; they show how this site separates analytical evidence, workflow and procurement claims.
| Supported by the study | Not supported by the study |
|---|---|
| High specificity (99.7%) for tongue swabs in the studied population | WHO policy recommendation for tongue swab TB testing |
| Sensitivity values with named reference standards and denominators | Regulatory authorization for clinical deployment in any jurisdiction |
| Sensitivity drop-off in smear-negative subgroups | Performance in asymptomatic screening or unstudied populations |
| Comparison of sputum vs. tongue swab within the same study | Replacement of sputum as the standard specimen for TB diagnosis |
6. Conclusions and Limitations
The multicenter prospective study demonstrates that the LyocartE MTB assay on tongue swabs achieves high specificity (99.7%) and moderate-to-high sensitivity (87.4% vs. sputum Xpert Ultra; 84.1% vs. composite microbiological reference standard) in 689 presumptive TB participants at three sites in China. The tongue swab sensitivity is lower than sputum sensitivity (95.2%) against the same composite reference, with a notable drop-off in smear-negative cases. These findings support further evaluation of tongue swabs as a complementary specimen type but do not support their use as a standalone replacement for sputum in all TB diagnostic workflows.
The study does not provide evidence for WHO endorsement, regulatory authorization, or performance in unstudied screening populations. Procurement decisions should incorporate regulatory status verification, population-specific operational validation, and WHO guidance where available.
Sources and References
- Primary source: Clinical Infectious Diseases, DOI: 10.1093/cid/ciag342 — Multicenter prospective diagnostic accuracy study (N=689, three sites in China, published May 29, 2026). Accessed August 7, 2026.
- Independent verification: PubMed E-utilities, PMID 42212698 — Confirms study existence, multicenter design, and enrollment size. Accessed August 7, 2026.
- FDA consumer guidance on medical device terminology: FDA — Are There FDA-Registered or FDA-Certified Medical Devices? — Context on why database listings are not equivalent to regulatory authorization. Accessed August 7, 2026.